All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Enoblituzumab Trial Ended Early Due to Safety Concerns in Head and Neck Squamous Cell Carcinoma

July 11th 2022

The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

American Oncology Network Physicians Research Presented at ASCO 2022

July 11th 2022

American Oncology Network, LLC is pleased to announce that three research studies co-authored by AON physicians were presented at the American Society of Clinical Oncology 2022 Annual Meeting, held June 3-7, 2022.

Practical Considerations for Fellows Treating VTE

July 11th 2022

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

The Podcast by Fellows for Fellows

July 10th 2022

Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.

If We Want to Be Heard, We Must Speak Up

July 9th 2022

Jill Gilbert, MD, urges healthcare providers to undertake the process of visible and courageous support of the truth in the medical field.

Nivolumab Plus Ipilimumab Displays Durable Benefit in MSI-H/dMMR mCRC

July 8th 2022

Nivolumab alone or in combination with ipilimumab continued to demonstrate sustained clinical benefit as second- and first-line therapy, respectively, in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Dostarlimab Produces Durable Responses With Acceptable Safety in dMMR Solid Tumors

July 8th 2022

Thierry André, MD, discusses the results of the phase 1 GARNET study with dostarlimab and the significance of these findings for patients with mismatch repair–deficient/microsatellite instqability–high solid tumors.

Anbalcabtagene Autoleucel Elicits Meaningful Responses in Relapsed/Refractory LBCL

July 8th 2022

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

In the Trenches With the Fellows

July 8th 2022

Mili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.

Neoadjuvant Nivolumab Plus Ipilimumab Elicits 100% Response Rate in dMMR Colon Cancer

July 8th 2022

The combination of nivolumab and ipilimumab generated a 100% response rate in patients with mismatch repair–deficient colon cancer and a 29% response rate in patients with MMR-proficient disease.

Rutgers Cancer Institute Research Leader Eileen White Named Rutgers Board of Governors Professor of Molecular Biology and Biochemistry

July 8th 2022

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

Machine Learning Develops Into a Powerful Tool in Cancer Care

July 8th 2022

The expansion of technology includes machine learning, which is quickly emerging as a dynamic aid for clinicians in every aspect of cancer care, from diagnosis to treatment decisions.

Belantamab Mafodotin Plus Lenalidomide/Dexamethasone Shows Efficacy, Safety in Newly Diagnosed Myeloma

July 8th 2022

The addition of belantamab mafodotin-blmf to lenalidomide and dexamethasone generated responses with acceptable safety in patients with newly diagnosed multiple myeloma who were ineligible to undergo autologous stem cell transplant.

FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors

July 7th 2022

The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors.

Real-World Patient Engagement Highlights Opportunities for Digital Care Integration

July 7th 2022

Digital health solutions have the potential to improve outcomes via remote symptom monitoring, increase patient/physician communication, and improve patient education.

Predictive ctDNA Testing Opens the Door for Increasingly Personalized Care in Colon Cancer

July 7th 2022

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

Nivolumab Plus FOLFOXIRI/Bevacizumab Elicits Promising Responses in RAS/BRAF-Mutated mCRC

July 7th 2022

The addition of nivolumab to FOLFOXIRI and bevacizumab resulted in encouraging responses when used as frontline treatment in patients with advanced or metastatic colorectal cancer harboring RAS or BRAF mutations, irrespective of microsatellite status.

Praluzatamab Ravtansine Generates Responses in HR-Positive, HER2-Negative Breast Cancer

July 7th 2022

Praluzatamab ravtansine achieved a promising overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Expanding Opportunities for Real-World Evidence in Oncology

July 7th 2022

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.